Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jun Gong MD

Jun Gong MD

Assistant Professor, Department of Medicine, Division of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, California

Jun Gong, MD, is an Assistant Professor in the Department of Medicine, Division of Hematology and Oncology at Cedars-Sinai Medical Center. As a medical oncologist, his primary clinical interests are in gastrointestinal (GI), hepatobiliary, and genitourinary (GU) cancers with a multidisciplinary focus of care along with colleagues from surgery, gastroenterology, radiation oncology, radiology, and urology. Dr. Gong is focused on translational and clinical cancer research with interests in early therapeutic trials (immunotherapy, targeted therapies, biologics, and other systemic therapies) and biomarker development to improve patient outcomes in GI and GU cancers. 

Disclosures

Consultant or Advisory Role – EMD Serono, Elsevier, Exelixis, QED Therapeutics, Natera, Basilea, HalioDx, Eisai, Janssen, Astellas, Amgen, Pfizer, Seagen, and Bayer.

Recent Contributions to PracticeUpdate:

  1. Association of Academic Rank and Productivity With Metrics of Twitter Utilization Among Kidney Cancer Specialists
  2. Medicaid Expansion Did Not Improve Time to Treatment for Young Patients With Metastatic RCC
  3. Tumor Endothelial ELTD1 as a Predictive Marker for Treatment of RCC Patients With Sunitinib
  4. First-Line Avelumab Plus Axitinib vs Sunitinib in Patients With Advanced Renal Cell Carcinoma
  5. Benign Renal Oncocytoma vs Chromophobe Renal Cell Carcinoma on Computed Tomography Using Deep Learning
  6. Improved Survival After Cytoreductive Nephrectomy for mRCC in the Contemporary Immunotherapy Era
  7. Prolonged Survival in Patients With mRCC and Pancreatic Metastases
  8. Atezolizumab Alone or With Bevacizumab vs Sunitinib in Previously Untreated mRCC
  9. COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced RCC
  10. No Direct Link Between PD-L1 Status and Tumor Mutation Burden With Clinical Benefit in mRCC

Elsewhere

Recently Updated